Serum C-reactive protein in adolescence and risk of schizophrenia in adulthood: A prospective birth cohort study

Brain, Behavior, and Immunity

Volumn 59, Issue , 2017, Pages 253-259

  Metcalf, Stephen A ^a   Jones, Peter B ^a   Nordstrom, Tanja ^b,c   Timonen, Markku ^b   Mäki, Pirjo ^{b,c,d,e,f,g,h}   Miettunen, Jouko ^b,c   Jääskeläinen, Erika ^b,c   Järvelin, Marjo Riitta ^b,c,i   Stochl, Jan ^a   Murray, Graham K ^a   Veijola, Juha ^b,c   Khandaker, Golam M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF OULU   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d Oulu University Hospital ^*  (Finland)

^e Middle Ostrobothnia Central Hospital   (Finland)

^f Mental Health Services Joint Municipal Authority of Wellbeing in Raahe District   (Finland)

^g Mental Health Services Basic Health Care District of Kallio   (Finland)

^h North Ostrobothnia Hospital District   (Finland)

ⁱ MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Adolescent; Adult; C reactive protein; Inflammatory markers; Longitudinal study; Psychotic disorders; Schizophrenia; Systemic inflammation

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CLASSIFICATION; EDUCATIONAL STATUS; FEMALE; FINLAND; HUMAN; ICD-10; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PSYCHOSIS; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING HABIT; SOCIAL STATUS; ADOLESCENT; BLOOD; CROSS-SECTIONAL STUDY; INTERNATIONAL CLASSIFICATION OF DISEASES; PSYCHOLOGICAL RATING SCALE; REGISTER; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; C-REACTIVE PROTEIN; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FINLAND; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; REGISTRIES; RISK; SCHIZOPHRENIA; YOUNG ADULT;

EID: 85006274257     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2016.09.008     Document Type: Article

References (56)

1. Bartova, L., Rajcani, J., Pogady, J., Herpes simplex virus antibodies in the cerebrospinal fluid of schizophrenic patients. Acta Virol. 31 (1987), 443–446.
2. Benros, M.E., Nielsen, P.R., Nordentoft, M., Eaton, W.W., Dalton, S.O., Mortensen, P.B., Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am. J. Psychiatry 168 (2011), 1303–1310.
3. Brown, A.S., Derkits, E.J., Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 167 (2010), 261–280.
4. Brown, A.S., Begg, M.D., Gravenstein, S., Schaefer, C.A., Wyatt, R.J., Bresnahan, M., Babulas, V.P., Susser, E.S., Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch. Gen. Psychiatry 61 (2004), 774–780.
5. Brown, A.S., Hooton, J., Schaefer, C.A., Zhang, H., Petkova, E., Babulas, V., Perrin, M., Gorman, J.M., Susser, E.S., Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am. J. Psychiatry 161 (2004), 889–895.
6. Buka, S.L., Tsuang, M.T., Torrey, E.F., Klebanoff, M.A., Bernstein, D., Yolken, R.H., Maternal infections and subsequent psychosis among offspring. Arch. Gen. Psychiatry 58 (2001), 1032–1037.
7. Buka, S.L., Tsuang, M.T., Torrey, E.F., Klebanoff, M.A., Wagner, R.L., Yolken, R.H., Maternal cytokine levels during pregnancy and adult psychosis. Brain Behav. Immun. 15 (2001), 411–420.
8. Canetta, S., Sourander, A., Surcel, H.M., Hinkka-Yli-Salomaki, S., Leiviska, J., Kellendonk, C., McKeague, I.W., Brown, A.S., Elevated maternal C-reactive protein and increased risk of schizophrenia in a national birth cohort. Am. J. Psychiatry 171 (2014), 960–968.
9. Chaudhry, I.B., Hallak, J., Husain, N., Minhas, F., Stirling, J., Richardson, P., Dursun, S., Dunn, G., Deakin, B., Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol. 26 (2012), 1185–1193.
10. Dalman, C., Allebeck, P., Gunnell, D., Harrison, G., Kristensson, K., Lewis, G., Lofving, S., Rasmussen, F., Wicks, S., Karlsson, H., Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. Am. J. Psychiatry 165 (2008), 59–65.
11. Danesh, J., Wheeler, J.G., Hirschfield, G.M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G.D., Pepys, M.B., Gudnason, V., C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350 (2004), 1387–1397.
12. Delisi, L.E., Smith, S.B., Hamovit, J.R., Maxwell, M.E., Goldin, L.R., Dingman, C.W., Gershon, E.S., Herpes simplex virus, cytomegalovirus and Epstein–Barr virus antibody titres in sera from schizophrenic patients. Psychol. Med. 16 (1986), 757–763.
13. Di Nicola, M., Cattaneo, A., Hepgul, N., Di Forti, M., Aitchison, K.J., Janiri, L., Murray, R.M., Dazzan, P., Pariante, C.M., Mondelli, V., Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav. Immun. 31 (2013), 90–95.
14. Dickerson, F., Stallings, C., Sullens, A., Origoni, A., Leister, F., Krivogorsky, B., Yolken, R., Association between cognitive functioning, exposure to herpes simplex virus type 1, and the COMT Val158Met genetic polymorphism in adults without a psychiatric disorder. Brain Behav. Immun. 22 (2008), 1103–1107.
15. Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Khushalani, S., Yolken, R., Additive effects of elevated C-reactive protein and exposure to herpes simplex virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr. Res. 134 (2012), 83–88.
16. Eaton, W.W., Byrne, M., Ewald, H., Mors, O., Chen, C.Y., Agerbo, E., Mortensen, P.B., Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am. J. Psychiatry 163 (2006), 521–528.
17. Ganguli, R., Yang, Z., Shurin, G., Chengappa, K.N., Brar, J.S., Gubbi, A.V., Rabin, B.S., Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. 51 (1994), 1–10.
18. Gardner, R.M., Dalman, C., Wicks, S., Lee, B.K., Karlsson, H., Neonatal levels of acute phase proteins and later risk of non-affective psychosis. Transl. Psychiatry, 3, 2013, e228.
19. Goldsmith, D.R., Rapaport, M.H., Miller, B.J., A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol. Psychiatry, 2016.
20. Gottesman, I.I., Sheilds, J., Schizophrenia: The Epigenetic Puzzle. 1982, Cambridge University Press, New York.
21. Hedberg, P., Ylitalo, K., Puukka, M., Highly sensitive determination of C-reactive protein on the Innotrac Aio! immunoanalyzer. Scand. J. Clin. Lab. Invest. 64 (2004), 677–685.
22. Karlsson, H., Blomstrom, A., Wicks, S., Yang, S., Yolken, R.H., Dalman, C., Maternal antibodies to dietary antigens and risk for nonaffective psychosis in offspring. Am. J. Psychiatry 169 (2012), 625–632.
23. Khandaker, G.M., Dantzer, R., Is there a role for immune-to-brain communication in schizophrenia?. Psychopharmacology 233 (2016), 1559–1573.
24. Khandaker, G.M., Zimbron, J., Dalman, C., Lewis, G., Jones, P.B., Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophr. Res. 139 (2012), 161–168.
25. Khandaker, G.M., Zimbron, J., Lewis, G., Jones, P.B., Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol. Med. 43 (2013), 239–257.
26. Khandaker, G.M., Pearson, R.M., Zammit, S., Lewis, G., Jones, P.B., Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 71 (2014), 1121–1128.
27. Khandaker, G.M., Zammit, S., Lewis, G., Jones, P.B., A population-based study of atopic disorders and inflammatory markers in childhood before psychotic experiences in adolescence. Schizophr. Res. 152 (2014), 139–145.
28. Khandaker, G.M., Cousins, L., Deakin, J., Lennox, B.R., Yolken, R., Jones, P.B., Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2 (2015), 258–270.
29. Khandaker, G.M., Stochl, J., Zammit, S., Lewis, G., Jones, P.B., A population-based prospective birth cohort study of childhood neurocognitive and psychological functioning in healthy survivors of early life meningitis. Ann. Epidemiol. 25 (2015), 236–242.
30. Laan, W., Grobbee, D.E., Selten, J.P., Heijnen, C.J., Kahn, R.S., Burger, H., Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 71 (2010), 520–527.
31. Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., Kron, S., A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry 71 (2010), 138–149.
32. Maes, M., Meltzer, H.Y., Bosmans, E., Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 89 (1994), 346–351.
33. Meyer, U., Nyffeler, M., Yee, B.K., Knuesel, I., Feldon, J., Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav. Immun. 22 (2008), 469–486.
34. Miller, B.J., Buckley, P., Seabolt, W., Mellor, A., Kirkpatrick, B., Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 70 (2011), 663–671.
35. Miller, B.J., Culpepper, N., Rapaport, M.H., C-reactive protein levels in schizophrenia. Clin. Schizophr. Relat. Psychoses, 2013, 1–22.
36. Mondelli, V., Ciufolini, S., Belvederi Murri, M., Bonaccorso, S., Di Forti, M., Giordano, A., Marques, T.R., Zunszain, P.A., Morgan, C., Murray, R.M., Pariante, C.M., Dazzan, P., Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophr. Bull. 41 (2015), 1162–1170.
37. Mortensen, P.B., Norgaard-Pedersen, B., Waltoft, B.L., Sorensen, T.L., Hougaard, D., Yolken, R.H., Early infections of Toxoplasma gondii and the later development of schizophrenia. Schizophr. Bull. 33 (2007), 741–744.
38. Muller, N., Riedel, M., Scheppach, C., Brandstatter, B., Sokullu, S., Krampe, K., Ulmschneider, M., Engel, R.R., Moller, H.J., Schwarz, M.J., Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry 159 (2002), 1029–1034.
39. Myint, A.M., Schwarz, M.J., Verkerk, R., Mueller, H.H., Zach, J., Scharpe, S., Steinbusch, H.W., Leonard, B.E., Kim, Y.K., Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav. Immun. 25 (2011), 1576–1581.
40. Pearson, T.A., Mensah, G.A., Alexander, R.W., Anderson, J.L., Cannon, R.O. 3rd, Criqui, M., Fadl, Y.Y., Fortmann, S.P., Hong, Y., Myers, G.L., Rifai, N., Smith, S.C. Jr., Taubert, K., Tracy, R.P., Vinicor, F., Centers for Disease, C., Prevention, American Heart, A., Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003), 499–511.
41. Pedersen, M.S., Benros, M.E., Agerbo, E., Borglum, A.D., Mortensen, P.B., Schizophrenia in patients with atopic disorders with particular emphasis on asthma: a Danish population-based study. Schizophr. Res. 138 (2012), 58–62.
42. Perala, J., Suvisaari, J., Saarni, S.I., Kuoppasalmi, K., Isometsa, E., Pirkola, S., Partonen, T., Tuulio-Henriksson, A., Hintikka, J., Kieseppa, T., Harkanen, T., Koskinen, S., Lonnqvist, J., Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch. Gen. Psychiatry 64 (2007), 19–28.
43. Pihlajamaa, J., Suvisaari, J., Henriksson, M., Heila, H., Karjalainen, E., Koskela, J., Cannon, M., Lonnqvist, J., The validity of schizophrenia diagnosis in the Finnish Hospital Discharge Register: findings from a 10-year birth cohort sample. Nord. J. Psychiatry 62 (2008), 198–203.
44. Potvin, S., Stip, E., Sepehry, A.A., Gendron, A., Bah, R., Kouassi, E., Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 63 (2008), 801–808.
45. Raison, C.L., Rutherford, R.E., Woolwine, B.J., Shuo, C., Schettler, P., Drake, D.F., Haroon, E., Miller, A.H., A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70 (2013), 31–41.
46. Salazar, J., Martinez, M.S., Chavez, M., Toledo, A., Anez, R., Torres, Y., Apruzzese, V., Silva, C., Rojas, J., Bermudez, V., C-reactive protein: clinical and epidemiological perspectives. Cardiol. Res. Pract., 2014, 2014, 605810.
47. Shi, L., Smith, S.E., Malkova, N., Tse, D., Su, Y., Patterson, P.H., Activation of the maternal immune system alters cerebellar development in the offspring. Brain Behav. Immun. 23 (2009), 116–123.
48. Sommer, I.E., van Westrhenen, R., Begemann, M.J., de Witte, L.D., Leucht, S., Kahn, R.S., Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr. Bull. 40 (2014), 181–191.
49. Steiner, J., Walter, M., Glanz, W., Sarnyai, Z., Bernstein, H.G., Vielhaber, S., Kastner, A., Skalej, M., Jordan, W., Schiltz, K., Klingbeil, C., Wandinger, K.P., Bogerts, B., Stoecker, W., Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 70 (2013), 271–278.
50. Sund, R., Quality of the Finnish Hospital Discharge Register: a systematic review. Scand. J. Public Health 40 (2012), 505–515.
51. Torrey, E.F., Bartko, J.J., Lun, Z.R., Yolken, R.H., Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr. Bull. 33 (2007), 729–736.
52. Upthegrove, R., Manzanares-Teson, N., Barnes, N.M., Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr. Res. 155 (2014), 101–108.
53. Weir, R.K., Forghany, R., Smith, S.E., Patterson, P.H., McAllister, A.K., Schumann, C.M., Bauman, M.D., Preliminary evidence of neuropathology in nonhuman primates prenatally exposed to maternal immune activation. Brain Behav. Immun. 48 (2015), 139–146.
54. WHO, The ICD-10 Classification of Mental and Behavioural Disorder: Clinical Descriptions and Diagnostic Guidelines. 1992, World Health Organization.
55. Wium-Andersen, M.K., Orsted, D.D., Nordestgaard, B.G., Elevated C-reactive protein associated with late- and very-late-onset schizophrenia in the general population: a prospective study. Schizophr. Bull. 40 (2014), 1117–1127.
56. Yeh, E.T., Willerson, J.T., Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 107 (2003), 370–371.